Full-Time
Site Process Safety Manager
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
No salary listed
Cork, Ireland
In Person
This is a site-based role.
Bachelor's
 Biology & Biotech (1) |
|---|
Get referred to AbbVie
See people who can refer or advise you
- A bachelor's degree or equivalent in Chemical Engineering, Process Engineering, Mechanical Engineering, Environmental Health & Safety, Occupational Health and Safety, or a related engineering or science discipline is required.
- At least 5 years of relevant experience in the process or pharmaceutical industry is required, including expertise in process safety management and EHS leadership.
- Strong working knowledge of process safety management principles and standards, including HAZOP, LOPA, ATEX, COMAH, IEC 61508/61511, and applicable Irish and European Union safety legislation is required.
- Experience managing EHS on construction, engineering, or capital projects within live operational or regulated industrial environments is required.
- Experience reviewing and approving method statements, job safety analyses, job hazard analyses, risk assessments, management of change documentation, and permit-to-work documentation for high-risk construction and maintenance activities is required.
- Strong knowledge of regulatory compliance frameworks, including construction safety legislation, environmental obligations, and contractor management, is required.
- The role requires communication, influencing, and stakeholder management skills to engage with contractors and senior leadership.
- Strong analytical and problem-solving skills, attention to detail, and a compliance mindset are required.
- Develop, implement, and continuously improve site process safety management systems, procedures, and standards to prevent major accidents and incidents in line with legal, site, and corporate requirements.
- Lead safe process design reviews and introduce new products and processes from a process safety perspective, ensuring hazards are identified and adequately controlled before operation.
- Chair, facilitate, and document HAZOPs, LOPAs, and other structured risk assessments across new and existing processes, and track action items through completion.
- Complete Pre-Startup Safety Reviews for new and modified processes, equipment, and facilities, ensuring safety-critical elements are verified before operations commence.
- Apply and maintain compliance with relevant process safety legislation and standards, including COMAH, ATEX, IEC 61508/61511, and applicable process safety management frameworks.
- Interact with management of change and change control processes, providing EHS approval and process safety input for significant changes affecting people, plant, process, or the environment.
- Review and maintain process safety documentation, including HAZOP reports, safety cases, relief system designs, and capital project lifecycle deliverables.
- Propose, develop, and drive implementation of process safety improvement initiatives across the site.
- Maintain process safety key performance indicators and metrics, and prepare and present regular performance reports to site leadership and global EHS teams.
- Engage with global process safety subject-matter experts and networks to benchmark performance, share learnings, and incorporate best practices on site.
- Maintain and enhance site emergency response plans, procedures, and preparedness arrangements, integrating project activities with live operational emergency response.
- Support business continuity planning from an EHS perspective by identifying and mitigating risks to continued safe operation during significant change or construction activity.
- Provide EHS support for product campaigns, ensuring process safety and emergency preparedness elements are addressed and communicated to relevant teams.
- Design and deliver process safety and EHS training programs for site personnel, contractors, and project teams.
- Plan and conduct EHS audits across the operational site and capital project, share findings, drive improvement actions, and support development of a proactive safety culture.
- Support safety investigations and troubleshooting activities, contributing technical process safety expertise to identify root causes and prevent recurrence.
- Contribute to continuous improvement of the site Safety Management System by identifying gaps and implementing enhancements aligned with regulatory changes and corporate standards.
- Experience supporting aseptic or pharmaceutical manufacturing projects in a Good Manufacturing Practice environment.
- Familiarity with brownfield project execution challenges, including segregation, interface management, and concurrent operations.
- Chartered Engineer status or progress toward chartership.
- Relevant professional certifications or memberships, such as CMIOSH or MIEI, or equivalent.
- Experience supporting major capital projects from design through startup and handover.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
- FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
- WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.
What critics are saying
- HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
- The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
- Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.
What makes AbbVie unique
- SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
- Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
- Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 3%AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.
AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals
AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.
UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -
AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.